Cargando…
Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin
BACKGROUND: Cisplatin (DDP)-based systemic chemotherapy has been widely used in the treatment of postoperative or advanced NSCLC patients, however, its effective rate is only 14~40%. HIF-2α can upregulate drug-resistant-related genes expression and lead to chemotherapy resistance in many tumors. How...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832106/ https://www.ncbi.nlm.nih.gov/pubmed/29469087 http://dx.doi.org/10.12659/MSM.906107 |
_version_ | 1783303261449617408 |
---|---|
author | Gao, Zhao-jia Yuan, Wei-dong Yuan, Jun-qiang Yuan, Kai Wang, Yong |
author_facet | Gao, Zhao-jia Yuan, Wei-dong Yuan, Jun-qiang Yuan, Kai Wang, Yong |
author_sort | Gao, Zhao-jia |
collection | PubMed |
description | BACKGROUND: Cisplatin (DDP)-based systemic chemotherapy has been widely used in the treatment of postoperative or advanced NSCLC patients, however, its effective rate is only 14~40%. HIF-2α can upregulate drug-resistant-related genes expression and lead to chemotherapy resistance in many tumors. However, little is known about the relationship between HIF-2α and chemotherapy resistance of lung cancer cells. MATERIAL/METHODS: In our study, the siRNA expression vectors targeting the HIF-2α gene were designed, constructed, and transfected into A549 cells. MTT assay and western blot analysis of P-glycoprotein 1 (P-gp) were used to explore the transfer influence of HIF-2α gene silencing on the A549 cells in the cisplatin-based chemotherapy resistance. RESULTS: After transfection with the siRNA(HIF-2α) into A549 cells, mRNA and protein expression of HIF-2α were downregulated. At the same time, expression of P-gp decreased significantly. Furthermore, the sensitivity to cisplatin significantly increased. CONCLUSIONS: The constructed siRNA expression vectors can effectively suppress the expression of HIF-2α and P-gp, which then can reverse the chemotherapy resistance of A549 cells. |
format | Online Article Text |
id | pubmed-5832106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58321062018-03-06 Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin Gao, Zhao-jia Yuan, Wei-dong Yuan, Jun-qiang Yuan, Kai Wang, Yong Med Sci Monit Lab/In Vitro Research BACKGROUND: Cisplatin (DDP)-based systemic chemotherapy has been widely used in the treatment of postoperative or advanced NSCLC patients, however, its effective rate is only 14~40%. HIF-2α can upregulate drug-resistant-related genes expression and lead to chemotherapy resistance in many tumors. However, little is known about the relationship between HIF-2α and chemotherapy resistance of lung cancer cells. MATERIAL/METHODS: In our study, the siRNA expression vectors targeting the HIF-2α gene were designed, constructed, and transfected into A549 cells. MTT assay and western blot analysis of P-glycoprotein 1 (P-gp) were used to explore the transfer influence of HIF-2α gene silencing on the A549 cells in the cisplatin-based chemotherapy resistance. RESULTS: After transfection with the siRNA(HIF-2α) into A549 cells, mRNA and protein expression of HIF-2α were downregulated. At the same time, expression of P-gp decreased significantly. Furthermore, the sensitivity to cisplatin significantly increased. CONCLUSIONS: The constructed siRNA expression vectors can effectively suppress the expression of HIF-2α and P-gp, which then can reverse the chemotherapy resistance of A549 cells. International Scientific Literature, Inc. 2018-02-22 /pmc/articles/PMC5832106/ /pubmed/29469087 http://dx.doi.org/10.12659/MSM.906107 Text en © Med Sci Monit, 2018 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Lab/In Vitro Research Gao, Zhao-jia Yuan, Wei-dong Yuan, Jun-qiang Yuan, Kai Wang, Yong Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin |
title | Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin |
title_full | Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin |
title_fullStr | Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin |
title_full_unstemmed | Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin |
title_short | Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin |
title_sort | downregulation of hif-2α reverse the chemotherapy resistance of lung adenocarcinoma a549 cells to cisplatin |
topic | Lab/In Vitro Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832106/ https://www.ncbi.nlm.nih.gov/pubmed/29469087 http://dx.doi.org/10.12659/MSM.906107 |
work_keys_str_mv | AT gaozhaojia downregulationofhif2areversethechemotherapyresistanceoflungadenocarcinomaa549cellstocisplatin AT yuanweidong downregulationofhif2areversethechemotherapyresistanceoflungadenocarcinomaa549cellstocisplatin AT yuanjunqiang downregulationofhif2areversethechemotherapyresistanceoflungadenocarcinomaa549cellstocisplatin AT yuankai downregulationofhif2areversethechemotherapyresistanceoflungadenocarcinomaa549cellstocisplatin AT wangyong downregulationofhif2areversethechemotherapyresistanceoflungadenocarcinomaa549cellstocisplatin |